SCHEMBL5085776

SCHEMBL5085776

O=C(c1ccccc1)c1ccc2nc3ccc(=O)cc-3oc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 12/20 0.61
CYP1A2 P05177 1/20 0.51
ALDH1A1 P00352 4/20 0.44
RAB9A P51151 3/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 1/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
MCL1 Q07820 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HPGD P15428 3/20 0.43
SCD O00767 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ABL1 P00519 1/20 0.41
FABP6 P51161 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9538200 0.87 APP (0.68) APPCYP1A2ALDH1A1POLBMEN1
SCHEMBL9538736 0.83 APP (0.66) APPCYP1A2ALDH1A1RAB9APOLB
Benzoic Acid SCHEMBL21043906 0.82 APP (0.78) APPCYP1A2ALDH1A1POLBMEN1
SCHEMBL19627052 0.81 APP (0.64) APPCYP1A2ALDH1A1POLBKDM4E
SCHEMBL19627048 0.81 APP (0.56) APPCYP1A2ALDH1A1RAB9AKDM4E
Pyridine SCHEMBL8601041 0.79 APP (0.54) APPCYP1A2ALDH1A1POLBMEN1
SCHEMBL563608 0.79 APP (0.63) APPCYP1A2ALDH1A1RAB9APOLB
Acetic Acid SCHEMBL233001 0.79 APP (0.59) APPCYP1A2ALDH1A1RAB9APOLB
SCHEMBL9749591 0.78 APP (0.59) APPCYP1A2LMNAHPGD
SCHEMBL8067 0.77 APP (0.65) APPCYP1A2ALDH1A1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE40387-E1 Pharmaceutical compositions, dosage forms and methods for oral administration of epothilones BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-17 US disclosed
US-6576651-B2 Such as (1S-(1R*,3R*(E),7R*,10S*,11R*,16S*))-7,11-dihydroxy 8,8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl) ethenyl-17-oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione; bioavailability BRISTOL-MYERS SQUIBB COMPANY 2003-06-10 US disclosed
WO-2002058699-A1 PHARMACEUTICAL FORMS OF EPOTHILONES FOR ORAL ADMINISTRATION BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-01 WO disclosed